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Signs of End of life in COPD: the value of collaberative care  
Chronic Obstructive Pulmonary Disease is the most common respiratory condition in the UK.  In a survey by the 
British Lung Foundation (2019) statistics show that 1.2 million people live with the condition.  The symptom burden 
in COPD  has been described as greater than that of Lung Cancer although comparatively the quality and amount of 
care that patient’s with COPD receive compares poorly (Crawford 2010: Diaz-Lobato et al 2015:White et al 2011). 
 End of life care (EOL)is used to describe care for people whose condition is in the terminal phase of illness (Russell 
2015: WHO 2017). Commencing EOL care early has been shown to be beneficial to those diagnosed with COPD 
(Higginson et al 2014).  It is the  heterogenous nature of COPD  which often makes it difficult to determine the stage 
a person has reached in the condition.  Some people with COPD present with a gradual decline,  others remain  
stable for years. Whilst a sub group presents with a  volatile form of COPD which requires hospital admission or 
respiratory support of some kind (Almagro et al 2017). It is the lack of clarity in some cases which means that end of 
life care  is often restricted  to the latter stages of the condition by which time the condition may have become 
terminal.  (Duenk et al 2016).   
 In order to implement EOL care requires a health care professional (HCP)  to make  forward planning with the 
patient in a   conducive setting not a respiratory ward or urgent care centre where important issues may not be 
included within the conversation. To establish satisfactory dialogue  includes  the frequency and quality of what  
topics are raised, and what are important to the patient, recognising this as a  two way process and there can be 
barriers to commencing this form of discussion.  A patient  may not want to talk about the deteriorating level of their 
condition which can present a dilemma for the HCP when to commence these discussions. However communication 
is but one component of holistic care management.  COPD has a  multi system impact and to provide appropriate  
and timely care  can incur the services of a range of health care professionals, utilising their observational skills to 
recognise care needs in order to enhance a person’s quality of life and address symptom changes. Multi disciplinary 
care was a target  of the 2011 Department of Health COPD strategy. (DOH 2011:Taveres et al 2017). This is a complex 
subject as managing  EOL care can be challenging  especially when COPD is advanced, and this paper will explore 
some of the physical indicators of   decline in a person with COPD..    
Exacerbations 
One of the indicators of  the last year of life is considered to be characterised by a gradual dependence on others for 
activities of daily living that worsens with each COPD exacerbation. COPD  is often unpredictable in nature and does 
not necessarily follow a specific course, differing from person to person (Gill et al 2010) The disease trajectory  is  
characterised by a decline in function with acute respiratory exacerbations. The uncertainties of the nature and 
progression of COPD makes decisions for EOL  challenging as these entry and re entry trajectories  involve episodic, 
acute exacerbations, which may  require re hospitalisation and can  ‘mask’ the steady decline of a patient’s condition 
(Choudhuri et al 2012).  Some people deteriorate slowly over a period of years, others may remain stable whilst a 
sub type will  have acute COPD exacerbations.  It is the variability of the condition which acts as a  hindrance for the 
health care professional to know  when to   initiate EOL care . This is coupled with a lack of prognostic tools specific 
to COPD that would guide a clinician when deciding on  end of life care (Choudhuri et al 2012). The variability of 
COPD symptoms supports the concept of multi disciplinary working.  In recognition that a range of HCP and 
subsequent services are required to identify and support  symptom changes to provide the right care accordingly.  
Also to address the variability of the condition multi disciplinary working was included as  one of the key concepts of 
the Department of Health COPD strategy in 2011.  
The definition for a COPD exacerbation is a worsening of a person’s condition from a stable state and 
beyond normal day to day variations to one that is acute in nature and that requires a change in 
medications (GOLD 2019;Wedzicha 2013)  The characteristics of COPD  is of  progressive , generally 
irreversible airflow limitation, due to an inflammatory response within the lungs with  increased incidence 
of exacerbations. (Wedzicha et al 2013).   Exacerbations characterise  the worsening of a persons condition 
and present with  a range of respiratory  symptoms which can  include an increase in breathlessness, 
mucous production and cough. Also other symptoms may  be more general and include fatigue and loss of 
appetite, all of which have an effect on a person’s quality of life, and in older people with COPD has a 
greater influence on their mortality.(Suissa et al 2012:Wedzicha et al 2007) The provision of care that 
reduces the rate of exacerbations has been shown to have a  direct effect on improvement of quality of 
life. However, there is no set consensus to define an exacerbation. Also a patient may struggle to 
determine an imminent exacerbation therefore not all exacerbations are recognised by the patient or 
reported and are therefore untreated(Pavord 2016).  
Exacerbation history and those  in a person’s recent past provide an indication whether end of life has 
been reached, these include  clustering of exacerbations which  are significant events in the patients 
overall prognosis: Suissa 2012)..   It is the  severity of the exacerbation and need for hospitalisation which 
are considered signs that a person is entering the final phase of the condition and  contribute to the 
assessment for end of life care (Hurst 2009:Wedzicha et al 2007).    Research has identified in some 
patients a 60% probability of mortality the year after hospitalisation due to an exacerbation(Suissa et al 
2012:Esteban et al 2018).  
   
Depression and anxiety 
symptoms such as depression and dyspnoea have been described as having an effect  on the  quality of life in those 
people with COPD.  Anxiety and depression have been related to worse health outcomes and this was raised as 
another  barrier with regard to initiating palliative care (Almagro et al 2017).  
The current focus of COPD tends to be related more on the  physical symptom management with often limited 
attention to the psychological symptoms of the condition despite the prevalence of psychological dysfunction 
(Yohannes et al 2014). Research has suggested that underdiagnosis and undertreatment of psychological disorders in 
COPD affects the overall quality of life of the person, and also are factors for readmission to hospital.  As these 
untreated symptoms can have an influence on day to day living (Salerno et al 2011:Cully 2006).    Also post traumatic 
stress  was identified in a study by Jones et al ( 2009). With  8% of the sample  used in the study showing symptoms.  
This was in people with COPD whose disease was stable, although the figure may be greater after an acute 
exacerbation and did  not form part of the research.  However, the psychological status of a person with COPD is not 
routinely measured although distress and fear are often reinforced by the reactions of others during an acute 
episode.  Also the changeability of the condition can  induce a constant state of hypervigilance to body changes and 
symptoms in the individual, and therefore induce greater stress (Almagro et al 2017).  
 
Sarcopenia and COPD 
The main symptom of COPD is characterised by breathlessness.  The added work of breathing coupled with a chronic 
inflammatory condition has the effect of increasing the bodies metabolic rate and raising the resting expenditure 
when compared to a healthy person.  Therefore  nutritional support is an important aspect of palliative care in this 
group of people and poor nutritional status is considered common amongst those with COPD.  (Sergei et al 2006).   
Various studies have identified that weight loss and reduced skeletal muscle mass are strong predictors of mortality 
risk in COPD  exacerbations. (Marquis et al 2002:Gronberg et al 2005:Sergei et al 2006). The reduction in body mass 
affects exercise tolerance  and  capacity, which can lead to a downward spiral of a person limiting their  activities of 
daily living and in turn increasing the possibility of exacerbations(Franssen et al 2008) 
COPD alone is considered  a disease of accelerated ageing, whilst Sarcopenia and poor nutritional status adds to the 
complexity. The wasting effects of  sarcopenia which involves the decline of lean and muscle mass is recognised as 
an age related condition and contributory factors which include physical inactivity, malnutrition and long term 
disease.   These people often present with greater  airflow obstruction, other symptoms include reduced quadriceps 
strength, loss of bone mineral density  and exercise capacity as opposed to those people  without sarcopenia. (Jones 
et al 2014).    The issue of frailty due to the  multi system dysfunction in the person with COPD  which do not relate 
to age also makes the person with COPD more at risk of a range of conditions include falls, and higher risk of 
infection (Gale et al 2017).  Although various research has supported the issue that those people with the  better 
prognosis had a lower incidence of sarcopenia as opposed to those with the worst prognosis (Jones et al 2014). 
Supporting the view that muscle dysfunction and low functional performance have been related to adverse 
outcomes in COPD (Rossi et al 2014: Schols et al 2005)    
   
 
Cognitive dysfunction  
The  nature of COPD  is associated with pulmonary and systemic inflammation, and  brain function can be vulnerable 
to changes in pathology. A growing volume of evidence has demonstrated an association between cognitive 
impairment which has been identified as being more prevalent in the person with COPD, indicating lung dysfunction 
as a specific  risk factor for poor cognition( Dodd 2015).. 
Various study’s have researched  cognitive impairment in those with COPD. Villeneuve demonstrated  that 36% of 
those  within a study sample presented with aspects of cognitive deficits. In comparison to 12% of individuals 
without COPD  amongst the general population but with cognitive deficits (Villeneuve et al 2012:Dodd 2015).  It has 
been suggested there may be a pattern of cognitive dysfunction caused by the effects of the condition coupled with 
the person in the  older age range, factors that can severely impact on managing  COPD (Dodd 2010).  
Although the definitive reason for cognitive decline  is not fully clear, the very nature of COPD may include co 
morbidities such as cardio vascular disease,  and include  hypertension which can affect cerebral  circulation 
(Vanfleteren 2015). Also cognitive dysfunction can affect  personality and  psychological profile, altering a persons 
level of conscientiousness, and their ability to adhere to medication regimes.  Poor medication adherence may be 
deliberate or accidental, due to forgetfulness or poor technique, but it  has an association with executive dysfunction  
affecting a person’s  overall quality of life (Brown et al 2017).  It is estimated  that only 1 in 10 patients with a 
metered-dose inhaler perform all of the steps correctly. The changes caused by cognitive dysfunction are another  
factor affecting  medication delivery,  and therapeutic management of  COPD (Chang et al 2012:Restrepo 2008: 
Lareau et al 2010).  Also communication difficulties during respiratory assessments may affect  the person’s ability to 
perform  instructions, causing inaccurate estimations of the disease staging and severity . Poor cognitive function 
affects a person’s ability to plan and sequence, and is a contributory factor  leading to increased rates of morbidity 
(Bourbeau et al 2008: Villeneuve et al 2012).  
 
Conclusion 
This paper has identified some of the physical indicators of end stage COPD although these can be variable.  Those 
symptoms that have been mentioned require a specialised approach, and a range of  skills  that the individual HCP 
may not possess.  COPD does not always follow a predictable course  differing from person to person which can 
cause problems for an HCP in determining the staging of the condition in order to implement EOL care.(Gill et al 
2010). There is also a lack of accurate prognostic tools in COPD which again adds to the difficulty of knowing when is 
the ‘right time’ to discuss EOL care(Taveres et al 2017). Multi disciplinary (MDT)working can assist when determining 
the condition stage that the  patient has reached, in order  to improve  quality of life and end of life 
care.(2011:Duenck et al 2017).  
However the provision of MDT services for COPD has been described as ‘patchy’ in the UK.  This is despite the high 
prevalence and health care burden of the disease (Chew et al 2018)  The Continuity of care that can be provided by 
MDT’s can have  a favourable influence on a person’s respiratory health. This was noted in patients who received 
care from  respiratory teams in acute care , with follow up in the community. (Esteban et al 2018.;DOH 2011).  
Therefore the  collective knowledge base and observational skills of an MDT can assist with care implementation 
with regard to EOL planning in recognition that   not all patients want to discuss EOL.  Also, some clinicians consider  
EOL conversations difficult to commence, regarding this as potentially destroying hope in a person(Reinke et al 
2011). However, when discussion does occur there is evidence of real benefit for the patient which includes higher 
health status and a higher quality of dying and death, in a life limiting condition (Reinke et al 2011:Taveres et al 
2017).    
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